Reply

Lauren A. Henderson(Boston Children's Hospital), Jay Mehta(Sardar Patel University), David R. Karp(The University of Texas Southwestern Medical Center), Adriana H. Tremoulet(George Washington University Hospital), Hamid Bassiri(Johnson & Johnson (United States)), Rae S. M. Yeung(University of Toronto), Kevin G. Friedman(Boston Children's Hospital), Anne Ferris(Stollery Children's Hospital), Philip Seo(Johns Hopkins University), Mark Gorelik(Morgan Stanley Children's Hospital), Scott Canna(Children's Hospital of Philadelphia), Sivia Lapidus(Hackensack University Medical Center), Grant S. Schulert(Cincinnati Children's Hospital Medical Center), Edward M. Behrens(Children's Hospital of Philadelphia), Mary Beth F. Son(Boston Children's Hospital)
Arthritis & Rheumatology
February 17, 2021
10.1002/art.41689
Cited by 1

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465